ADHD Therapeutics Market is expected to exhibit significant growth over the forecast period. The market was valued at approximately USD 19.7 billion in 2018 and is projected to register a 6.8% CAGR over the forecast period.
Attention-Deficit/Hyperactivity Disorder (ADHD) is a brain disorder, in which there is an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development.
Factors such as the rising prevalence of ADHD, rising use of additives & preservatives in children’s diet and increasing awareness regarding ADHD are expected to propel the growth of the market.
The existence of comorbid conditions in children leads to underdiagnoses of ADHD. This factor hampers the market growth during the forecast period. Moreover, limited availability of non-stimulant drugs is expected to adversely affect the market.
ADHD Therapeutics Market Segmentation
The global ADHD therapeutics market has been segmented into drug type, age-group, end-user, and region.
Based on drug type, the global ADHD therapeutics market has been divided into stimulants and non-stimulants. The stimulants segment further sub-segmented into amphetamine, methylphenidate, dextroamphetamine, dexmethylphenidate, lisdexamfetamine, and others. The lisdexamfetamine sub-segment is expected to be the largest segment owing to the high preference of the drug by doctors. Non-stimulants are further segmented into atomoxetine, bupropion, guanfacine, and clonidine.
The global ADHD therapeutics market, by treatment, has been bifurcated into pediatric & adolescents and adults.
The global ADHD therapeutics market, by end user, has been segmented into specialty clinics, hospitals & clinics, and others.
The ADHD Therapeutics Market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The ADHD therapeutics market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.
The European ADHD therapeutics market has been segmented into Western Europe and Eastern Europe. The market in Western Europe has further been classified into France, Germany, Spain, the UK, Italy, and the rest of Western Europe.
The ADHD therapeutics market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
The Middle East & Africa ADHD therapeutics market is segmented into the Middle East and Africa.
ADHD Therapeutics Market Key Players
Advanz Pharmaceutical (Canada), Eli Lilly and Company (US), Highland Therapeutics Inc. (Canada), Janssen Pharmaceuticals, Inc. (Belgium), NEOS Therapeutics, Inc. (US), Pfizer Inc. (US), Novartis AG (Switzerland), Noven Pharmaceuticals, Inc. (US), Shire (US), Teva Pharmaceutical Industries Ltd. (Israel), Impax Laboratories, LLC (US), GlaxoSmithKline plc (UK) and Purdue Pharma L.P. (US) are some of the key players operating in the global ADHD therapeutics market.
Global ADHD Therapeutics Market, by Drug Type
- Stimulants
- Amphetamine
- Methylphenidate
- Dextroamphetamine
- Dexmethylphenidate
- Lisdexamfetamine
- Other
- Non-StimulantsAtomoxetine
- Bupropion
- Guanfacine
- Clonidine
Global ADHD Therapeutics Market, by Age Group
- Pediatric and Adolescents
- Adults
Global ADHD Therapeutics Market, by End User
- Specialty Clinics
- Hospital Pharmacies
- Retail Pharmacies
- Others
Request Customization
Get a Sample
Get a Sample
Request Customization